Latest Multiple myeloma Stories

NEW YORK, Dec. 5, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) (the "Company") today announced that the following abstracts on perifosine, the Company's novel, potentially first-in-class, oral anti-cancer drug candidate that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, have been selected for presentation during the upcoming 53rd Annual Meeting of the American Society of Hematology (ASH), to be held December 10 -13,...

QUÉBEC CITY, Dec. 5, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the following presentations on perifosine, its novel, oral anticancer Akt inhibitor, at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 10 -13, 2011, at the San Diego Convention Center in San Diego, California: Abstract #815: "Perifosine Plus Bortezomib and Dexamethasone in...

NEW YORK, Nov. 29, 2011 /PRNewswire/ -- Senesco Technologies, Inc. (NYSE AMEX: SNT) announced that that Leslie J. Browne, Ph.D., President and CEO, will present at RetailInvestorConferences.com. DATE: December 1, 2011TIME: 10:00 AM ESTLINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button. This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall...

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submission for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. "The FDA's acceptance of the new drug application submission for carfilzomib marks an important milestone for bringing this...

All amounts are in U.S. dollars QUEBEC CITY, Nov. 23, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) announce today the signing of an exclusive commercialization and licensing agreement for the registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for the MENA (Middle East and North Africa) region. Perifosine, a novel oral Akt inhibitor, is currently in two...

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011, at the San Diego Convention Center in San Diego, CA. "The results being presented at ASH demonstrate carfilzomib's potential activity along all lines of multiple myeloma, and we are...

(Ivanhoe Newswire) -- A new study shows older blood cancer patients should be able to receive stem cell transplants no matter what age group they are in– 60 to 64, 65 to 69 or 70 to 75. Patients in all three age groups had comparable survival rates, suggesting  age played a limited role in how patients tolerate the mini-transplant, a "kinder, gentler" form of allogeneic (donor cell) stem cell transplantation developed at Fred Hutchinson Cancer Research Center. "Age is no longer a...

Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies, according to a study in the...

Study details outcomes of patients who received the 'mini transplant' developed at Fred Hutchinson Cancer Research Center Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That's the conclusion of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 and over who were treated with the mini-transplant, a "kinder, gentler"...

WHITE PLAINS, N.Y., Oct. 21, 2011 /PRNewswire/ -- Make like a vampire this Halloween and bite cancer back by participating in The Leukemia & Lymphoma Society's (LLS) Cancer Bites campaign. Vampire fans are uniting in the fight against cancer by raising money through their personal web pages, where they can post photos of their scariest or kookiest Halloween costumes while raising money from friends and family to support cancer research. Visit www.lls.org/cancerbites to learn more and to...